Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials

PLoS One. 2015 Mar 19;10(3):e0121632. doi: 10.1371/journal.pone.0121632. eCollection 2015.

Abstract

Background: Perinatal or mother-to-child transmission of hepatitis B virus (HBV) results in a high frequency of chronic infection. Risk of mother-to-child transmission is associated with maternal viral factors including hepatitis B e antigen (HBeAg) positivity and viral load.

Aim: To investigate associations between age, HBeAg status, HBV DNA levels and genotype in female patients screened for inclusion into two contemporary, randomized HBV trials.

Methods: Retrospective analyses focused on differences between women of childbearing age (≤44 years) and older women. Female patients (N = 355; 18-69 years) were included in the analysis: 41.7% of patients were Asian. In total, 44.4% were HBeAg-positive.

Results: Significantly more women aged ≤44 years were HBeAg-positive compared to women ≥45 years (57.2% versus 27.5%, respectively, p<0.0001), this proportion declined with increasing age. Younger women were significantly more likely to have high HBV viral load (HBV DNA>108 copies mL: ≤44 years 46.0% vs ≥45 years 25.5%, respectively; p<0.0001), and this declined with increasing age. HBeAg positivity was slightly higher in Asian women, associated with a higher proportion of HBV genotypes B and C in this population. There was no obvious relationship between genotype and viral load.

Conclusions: Women of childbearing age with CHB are more likely to have high HBV viral load and HBeAg positivity than older women; this likelihood decreases with age. Maternal serological and virological status should therefore be established early in pregnancy, taking into account age and genotype, and a risk-reducing strategy implemented in any patient who is HBeAg positive and has a high viral load.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • DNA, Viral / metabolism*
  • Female
  • Genotype*
  • Hepatitis B e Antigens / metabolism*
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / immunology
  • Hepatitis B virus / physiology*
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / genetics*
  • Humans
  • Middle Aged
  • Patient Selection*
  • Pregnancy
  • Retrospective Studies
  • Viral Load / drug effects
  • Young Adult

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B e Antigens

Grants and funding

This study was funded by Gilead Sciences (www.Gilead.com), Foster City, USA. (Study 102; NCT00117676, Study 103; NCT00116805) The writing of this paper was funded by Gilead Sciences, Foster City, USA. Initial data analyses were undertaken by and funded by Gilead Sciences. The funders participated in the study design and data collection and analysis, and funded editorial assistance with the preparation of the manuscript. The decision to publish was the sole responsibility of the authors.